艾伯维公司 ABBV 深 沪
等待开盘 01-30 09:30:00 美东时间
220.43
+1.760
+0.80%
华盛通- 最 高224.14
- 今 开218.00
- 成交量 783.40万股
- 最 低 218.00
- 昨 收 218.67
- 总市值 3895.00亿
- 52周最高 241.44
- 市盈率 静 92.22
- 换手率 0.00%
- 52周最低 157.74
- 委 比 33.33%
- 总股本 17.67亿
- 历史最高 241.44
- 量 比 1.35
- 振 幅 2.81%
- 历史最低 -18.61
- 每 手 1
- 风险率 19.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors recommended staying long on AbbVie.
01-28 21:20
BUZZ-U.S. drugmakers slip as 2028 Medicare price list adds 15 medicines
BUZZ-U.S. drugmakers slip as 2028 Medicare price list adds 15 medicines ** Shares of AbbVie ABBV.N , Gilead GILD.O , Merck MRK.N , Bristol Myers BMY.N , Lilly LLY.N , Pfizer PFE.N , Takeda TAK.N , GSK GSK.N down ~1% premarket ** U.S. officials named 15 drugs for 2028 Medicare price talks, including
01-28 19:29
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly LLY.N , Pfizer PFE.N and AbbVie ABBV.N for the
01-28 05:45
Citigroup Maintains Neutral on AbbVie, Lowers Price Target to $230
Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $235 to $230.
01-27 23:08
AbbVie Advances Early-Stage ABBV-722 Tablet Study, Underscoring Pipeline Momentum
Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overv...
01-27 00:33
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
<p><p>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced it will report its fourth quarter and full year 2025 financial results on Feb. 11, 2026, before U.S. markets open. A conference call and webcast will be held at 8:00 a.m. ET that day. Call details and webcast access are available on the company’s website. Highlights include: - Financial results release - Conference call/webcast at 8:00 a.m. ET on Feb. ...
01-20 21:15
期权扫描 | 空头占据高地！Meta、微软看跌期权占比均升至近7成；台积电财报引爆一巨量Call单
空头占据高地！Meta、微软看跌期权占比均升至近7成；奈飞豪掷70亿美元与索尼达成重磅交易，仍遭市场押注续跌；台积电财报引爆一巨量Call单，市场押注继续冲高？>>
01-16 11:32
AbbVie Targets Sleep Problems in Advanced Parkinson’s With Real‑World Foslevodopa/Foscarbidopa Study
Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overv...
01-16 00:35
艾伯维与特朗普政府达成协议，降低药价并承诺在美投资1000亿美元
美国制药巨头艾伯维公司周一表示，已与特朗普政府达成一项为期三年的协议，通过TrumpRx处方药直销平台为医疗补助计划（Medicaid）提供低价药品，并承诺...
01-13 08:27
